Related Experiment Video
Updated: Dec 6, 2025
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Nogo-A/S1PR2 Signaling Pathway Inactivation Decreases Microvascular Damage and Enhances Microvascular Regeneration in
Hongmei Tang1, Yunxian Xu2, Liru Liu1
1Department of Rehabilitation, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China.
Abstract:
The incidence of mild cognitive impairment in Parkinson's disease (PDMCI) is as high as 18-55%. However, the pathological mechanism of PDMCI is not yet clear. Our previous research showed that microvascular pathology and chronic cerebral hypoperfusion participated in the occurrence and development of PDMCI. Nogo-A has been suggested to be a negative regulator of microvascular regeneration in the central nervous system. Moreover, few insights have illuminated the mechanisms of Nogo-A and microvascular pathology in PDMCI. Therefore, we hypothesized that Nogo-A might be involved in the negative regulation of PDMCI angiogenesis. In this study, C57BL/6J mice were injected with Nogo-A-specific short hairpin RNA (shRNA-Nogo-A) in the lateral ventricle and intraperitoneally injected with a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and probenecid. Subjects were classified into the following five groups for the Morris water maze test: control (CON), CON + shRNA-GFP, CON + shRNA-Nogo-A, PDMCI, and PDMCI + shRNA-Nogo-A. Furthermore, blood-brain barrier (BBB) permeability, fluorescein isothiocyanate (FITC)-conjugated dextran, transmission electron microscopy (TEM), immunofluorescence and Western blot analyses were performed. The results showed that MPTP could cause spatial memory and behavioral impairment, significant microvascular impairment and increased Nogo-A expression. When Nogo-A expression was downregulated, the cognitive and microvascular impairments were alleviated, and the expression of sphingosine-1-phosphate receptor 2 (S1PR2) and the RhoA/ROCK signaling pathway were inhibited. These findings suggested that Nogo-A could bind to S1PR2, activate related signaling pathways, and lead to the inhibition of vascular remodeling in PDMCI mice. This study indicated that Nogo-A downregulation could mediate microvascular remodeling and provide further insights into the pathogenesis of PDMCI.
Insights
Downregulating Nogo-A protein in Parkinson's disease with mild cognitive impairment (PDMCI) models improved cognitive function and microvascular health. This suggests Nogo-A inhibition is a potential therapeutic strategy for PDMCI.
Area of Science:
- Neuroscience
- Pathology
- Vascular Biology
Background:
- Mild cognitive impairment in Parkinson's disease (PDMCI) affects 18-55% of patients, with unclear pathological mechanisms.
- Previous research links PDMCI to microvascular pathology and chronic cerebral hypoperfusion.
- Nogo-A, a regulator of central nervous system microvascular regeneration, is implicated but its role in PDMCI remains unclear.
Purpose of the Study:
- To investigate the hypothesis that Nogo-A negatively regulates angiogenesis in Parkinson's disease with mild cognitive impairment (PDMCI).
- To explore the mechanisms of Nogo-A and microvascular pathology in PDMCI.
- To assess the therapeutic potential of Nogo-A downregulation in PDMCI.
Main Methods:
- A mouse model of PDMCI was established using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and probenecid.
- Nogo-A was downregulated using Nogo-A-specific short hairpin RNA (shRNA-Nogo-A).
- Cognitive function was assessed using the Morris water maze test. Microvascular integrity, blood-brain barrier permeability, and molecular pathways (S1PR2, RhoA/ROCK) were analyzed using techniques including transmission electron microscopy and Western blot.
Main Results:
- MPTP induced spatial memory and behavioral impairments, significant microvascular damage, and increased Nogo-A expression in mice.
- Downregulation of Nogo-A alleviated cognitive deficits and microvascular impairments.
- Nogo-A inhibition suppressed sphingosine-1-phosphate receptor 2 (S1PR2) expression and the RhoA/ROCK signaling pathway.
Conclusions:
- Nogo-A appears to bind to S1PR2, activating signaling pathways that inhibit vascular remodeling in PDMCI.
- Downregulating Nogo-A promotes microvascular remodeling and ameliorates cognitive and microvascular impairments in PDMCI.
- Nogo-A is a potential therapeutic target for improving microvascular function and cognitive deficits in Parkinson's disease.
